307 related articles for article (PubMed ID: 33045134)
1. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
[TBL] [Abstract][Full Text] [Related]
4. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
5. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.
Yang L; Liu H; Xu XH; Wang XF; Huang HM; Shi WY; Jiang SH
Med Oncol; 2013 Dec; 30(4):720. PubMed ID: 24062259
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
9. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
[TBL] [Abstract][Full Text] [Related]
12. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
13. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
17. DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma.
Zhang L; Shangguan C; Li X; Li L; Wang X; Fu X; Sun Z; Shi Y; Wu J; Zhang X; Yu H; Nan F; Yan J; Chang Y; Zhou Z; Wu X; Feng X; Liu X; Xue H; Zou L; Lu Y; Wang J; Wang G; Li W; Zhang M
Leuk Res; 2022 Jul; 118():106881. PubMed ID: 35688096
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ
Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
20. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.
Brammer JE; Chihara D; Poon LM; Caimi P; de Lima M; Ledesma C; Rondon G; Ciurea SO; Nieto Y; Fanale M; Dabaja B; Maziarz RT; Champlin RE; Hosing C; Oki Y
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e41-e50. PubMed ID: 29277360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]